ERBB2 and breast carcinoma: These features could be detecting increasingly disordered enhancement gradients among nonresponders because of increased peritumoral vascularity and vascular invasion, an established marker of poor prognosis and risk of recurrence in HR+, HER2− breast cancers [48, 49].